Dr Syed Raza graduated from Aligarh University in India in 1993. After completing his postgraduate degree in Medicine from the same university, he moved to the UK for higher specialist studies. He successfully completed MRCP and CCT and later also awarded Fellow of the Royal College of Physicians of Edinburgh (FRCP ). He was awarded professor John Goodwin prize for outstanding performance in Diploma Cardiology exam at Hammersmith Hospital, University of London in 2001. Dr Raza is Fellow of American College of Cardiology and American College of Chest Physicoans . He is also Fellow of European Society of Cardiology and Fellow of European Society of Cardiovascular Imaging. He is also on the committee of Acute Cardiovascular Care. Heart Failure and Cardiovascular Imaging ( European Society of Cardiology )
He is currently working as Consultant Cardiologist and Head of the department of Medicine at Awali Hospital, Bahrain. Dr Raza is a board member of the Hospital Excecutive Committee . He also chairs the Resuscitation committee and Privileging and Credentialing Committee.
Prior to this he worked as consultant in Cardiology at Mid Cheshire Hospitals, NHS trust , United Kingdom.
He is the regional educational coordinator for RCP Edinburgh and examiner for MRCP exam for the Royal College of Physicians of UK. He has partipcpated in some well known trials and reasearch. He has to his credit numerous publications and he has presented his scietific work in different parts of the world. He is peer review author for some well respected International journals.
He is permanent Review author for abstracts for European Society of Cardiology Annual Congress. He is on the editorial board of International Journal of Endovasculat Treatment and Innovative Techniques . Dr Raza is a teaching faculty member for Healthcare Management and Leadership at Westford University , Dubai campus. He is certified American Board in Medical Quality . Dr Raza frequently organises a number of seminars, webinars , symposia and workshop on various healthcare , quality and safety topics . Dr Raza has led the first awareness campaign in Heart Failure in the Middle East in 2017 and regularly organises events to increase awareness about heart health . He recently organised CPR and AED training for general public in a community event, He is chairman of BAPCO's health promotion unit. His special interests are Cardiovascular Imaging, Heart Failure and Acute Cardiovascular Care. He is founder and chairman of Raza Foundations which works for educating and increasing awareness on various health related topics amongst the general public as well as provide free healthcare services to poor as one of the charity initiatives .
He is author of two books
1.Battling with COVID – my personal stories – published in 2022 2.Communication and Presentation Skills for Healthcare Professionals – published 2023
Cardiovascular Imaging, Heart Failure and Acute Cardiovascular Care
SGLT2 Inhibitors: Antidiabetic or Heart Failure Medication - Evidence from recent trials
Heart failure (HF) and Type 2 Diabetes Mellitus (T2DM) remain associated with increased mortality and morbidity, worldwide .
Recently, several prospective clinical trials involving SGLT2 inhibitors have also. demonstrated beneficial CV and renal effects CV effects have been reported in HF with significantly reduced ejection fraction (EF), demonstrating beneficial effects. irrespective of their hypoglycemic actions. Part of their beneficial effects comes from natriuresis and osmotic diuresis, influence on ion homeostasis, anti- inflammatory and antifibrotic effects. So far, cardio protection offered by these. drugs seem to be a combination of both systemic and molecular mechanisms. . Questions are being asked: can SGLT2 inhibitors become ‘statins’ for primary prevention of heart failure? Are SGLT2 inhibitors antidiabetics or heart failure medications? A meta-analysis of twelve RCTs encompassing 59,825 patients at different stages of HF and DM was done. Out of these, 32,448 were placed in treatment (with SGLT2 inhibitors) groups, while 27,377 patients were controls. Regardless of severity of HF or DM status, treatment groups showed a significantly less risk difference (RD) for CVDs and hospitalization for HF (HHF), than controls. The results were the same in diabetic patients who received SGLT2 inhibitors regardless of the severity of HF. The results favor the use of SGLT2 inhibitor as compared to control medication5. Based on such evidence, it is safe to say that SGLT2 inhibitors are antidiabetic but now may be termed heart failure medication where they improve cardiovascular outcomes and reduce hospitalization in HF, irrespective of severity and diabetes status.